Publications by authors named "G A Giridharan"

Background: Predicting hemolysis numerically based on the power-law model using idealized coefficients obtained from simplified devices yields a large variability in hemolysis index predictions. A computational fluid dynamics (CFD)-based Kriging surrogate modeling approach, developed by Craven et al. at the US Food & Drug Administration (FDA), was applied to a Fontan cavopulmonary assist device (CPAD) to generate device-specific hemolysis power-law coefficients.

View Article and Find Full Text PDF

Objective: After Fontan palliation, patients with single-ventricle physiology are committed to chronic circulatory inefficiency for the duration of their lives. This is due in large part to the lack of a subpulmonary ventricle. A low-pressure rise cavopulmonary assist device can address the subpulmonary deficit and offset the Fontan paradox.

View Article and Find Full Text PDF

Continuous-flow ventricular assist devices (CFVAD) and counterpulsation devices (CPD) are used to treat heart failure (HF). CFVAD can diminish pulsatility, but pulsatile modes have been implemented to increase vascular pulsatility. The effects of CFVAD in a pulsatile mode and CPD support on the function of endothelial cells (ECs) are yet to be investigated.

View Article and Find Full Text PDF

Testing drugs in vivo and in vitro have been essential elements for the discovery of new therapeutics. Due to the recent advances in in vitro cell culture models, such as human-induced pluripotent stem cell-derived cardiomyocytes and 3D multicell type organoid culture methods, the detection of adverse cardiac events prior to human clinical trials has improved. However, there are still numerous therapeutics whose adverse cardiac effects are not detected until human trials due to the inability of these cell cultures to fully model the complex multicellular organization of an intact human myocardium.

View Article and Find Full Text PDF